

## CURRICULUM VITAE

- Name:** Dima Simona Olimpia
- Date and place of birth:** 11 October 1967, Constanta
- Citizenship:** Romanian
- Fundeni Clinical Institute, 258 Fundeni street, Bucharest, Romania, zip code 022328, [www.icfundeni.ro](http://www.icfundeni.ro)
- Current position:**  
Scientific Researcher I, Fundeni Clinical Institute,  
Coordinator Research and Development Center of Digestive Disease and Liver Transplantation  
MD, PhD General Surgery, Fundeni Clinical Institute  
President of the Scientific Council, Fundeni Clinical Institute (since 2017)  
Scientific Coordinator of the project: POS CCE Priority Axis 2: Competitiveness through Research, Technological Development and Innovation, Operation: 2.2.1. Development of the existing C-D infrastructure and creation of new C-D infrastructures (laboratories, research centres) - 951 / code SMIS-CSNR 14056, financing contract no. 434 / 21.12.2012 - Centre of Excellence in Translational Medicine (CEMT).
- Scientific degree:**  
Ph.D. degree in 2006 (Minister's order number 632/21.03.2007), with the thesis entitled "Experimental models in the whole pancreas and islet cell transplantation" at Ovidius University, Constanta, coordinated by Prof. Dr. Vasile Sarbu  
Habilitation doctor in Medicine 2017
- Educational background & professional experience**

<b>Institution</b>	<b>Period</b>	<b>Degrees or diplomas obtained</b>
Carol Davila University of Medicine and Pharmacy, Faculty of General Medicine, Bucharest	1989–1995	MD degree, General Medicine
"Ovidius" University Constanta	1998–2006	PhD in Medical Sciences
<b>Institution</b>	<b>Period</b>	<b>Position</b>
County Clinical Hospital, Constanta	1995-1999	Attending surgeon
"Ovidius" University Constanta Faculty of General Medicine	2003–2006	CP III, MD General Surgery
Fundeni Clinical Institute, Bucharest	2006-Present	MD General Surgery
Fundeni Clinical Institute, Bucharest	2009–Present	Research & Development Coordinator
Fundeni Clinical Institute, Bucharest	2013-2015	CSII
Fundeni Clinical Institute, Bucharest	2015- Present	CSI
Fundeni Clinical Institute, Bucharest	2017- Present	President of the Scientific Council

- Competence, Honors**  
Secretary of the Commission 3, Life and Health, of the Consultative College of MCT (Minister of Education, Research and Youth) - Order of the Minister of Education, Research and Youth No. 965 of 4.05.2007 (2007-2014)  
Advisory Board of MCT (2012-2015).  
Research and Development Director of the Institute of Digestive Disease and Liver Transplantation (2009-2011)  
Scientific Coordinator of the project: POS CCE Priority Axis 2: Competitiveness through Research, Technological Development and Innovation, Operation: 2.2.1. Development of the existing C-D infrastructure and creation of new

C-D infrastructures (laboratories, research centres) - 951 / code SMIS-CSNR 14056, financing contract no. 434 / 21.12.2012 - Centre of Excellence in Translational Medicine (CEMT) (since 2012)

**Member:** Romanian Academy of Medical Sciences (since 2017)

**Member** of the editorial Board of SGO

**9. Other Specializations and Qualifications:**

2002-Specialization in Transplantation of Pancreatic Islets- Course and basic research in isolation, purification, cultivation and cryopreservation of pancreatic islets.

2002-2003: Training in liver surgery and liver transplantation at Fundeni Clinical Institute

2003-Training for isolation of pancreatic islets, within the Transplant and Cell Isolation Center, Department of Surgery, Geneva University Hospital, Switzerland.

2004-Visiting research fellow in clinical islet transplantation at the Islet Cell Resource Center (SC-ICR) in Southern California, the Department of Diabetes, Endocrinology and Metabolism, Genetics and Diabetes Research Center Leslie and Susan Gonda, California, USA.

2006–2007-Training Course on Organ Transplantation of the European Society for Organ Transplantation. Session I - Lyon, France Session II Malmo, Sweden.

June 2007- Sept 2007 Specialization degree in pancreas transplantation- Institute of Diabetes for Immunology and Transplantation, Minnesota University, USA

2009- Training course for the European Diploma in the Transplant Surgery Division of the European Union of Medical Specialists "Union of European Médecins Spécialistes (UEMS)" and European Surgery Council, Semmelweis University, Hungary.

**10. Research support by national / international programs / projects (Selection):**

Programme/Project	Position	Period	Budget (Ron)
PNCD II P024 "Comparative study of the molecular mechanisms of chronic pancreatitis and pancreatic ductal adenocarcinoma", (MOLPANC). <b>Publications:</b> An Exploratory Study of Inflammatory Cytokines as Prognostic Biomarkers in Patients with Ductal Pancreatic Adenocarcinoma. <b>Dima S.</b> et al. <a href="#">Pancreas</a> . 2012 Oct; <b>41(7)</b> :1001-7. <b>IF:3.008</b> Characterization of functional transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells. Cucu D, <b>Dima S</b> , et al. <a href="#">Pancreas</a> . 2014 Jul; <b>43(5)</b> :795-800. <b>IF:3.008</b>	Project director	2007-2010	2.000.000
Pr. no. 4 SEE: "Hepatocellular carcinoma stratification based on noninvasive markers" ( <a href="#">HEPMARK</a> );	Scientific responsible	2014-2017	4.945.612
PCCA-90: „Role of S100A4 and MAP4K4 in pancreatic ductal adenocarcinoma progression" PNII-PT-PCCA 90/2012	Scientific responsible	2012-2015	3.000.000
CEEX, Module I P62 "Genic profiles induced by transcriptional suppression of Ets-1 in pancreatic cancer"; (PACAGENTER). <b>Publication:</b> Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer. Lefter LP, <b>Dima S</b> , et al. <a href="#">Cancer Gene Ther</a> . 2009, 16(2):137-48. IF:3.887, Times cited:12	Scientific responsible	2006-2008	1.500.000

CEEX, Module I P64 "Caveolins 1, 2 and 3 expression in pancreatic cancers, molecular targets in diagnosis and therapy", (CAVEEX). <b>Publications:</b> Chapter 11: Chronic Pancreatitis as an Inductor of Pancreatic Cancer Correlations With Inflammatory Pathway, <b>Dima SO</b> , et al. <b>Book</b> Acute and Chronic Pancreatitis. <i>InTech</i> , 2015. Pancreatic metastases originating from uterine leiomyosarcoma: a case <b>Dima SO</b> , et al. <i>World J. Surg. Oncol.</i> 2014; 12: 405. IF: 1.408. Characterization of functional transient receptor potential melastatin 8 channels in human pancreatic ductal adenocarcinoma cells. Cucu D, <b>Dima SO</b> , et al. <i>Pancreas</i> , 43: 795-800, 2014. IF: 3.008	Scientific responsible	2006-2008	1.500.000
CEEX 56/2005 „Gene Expression Profile And Biomarkers Study Correlated With Clinic-pathological Parameters In Pancreatic Cancer”(GENOPACT)	Project member	2005-2008	15.000.000
Pr. no. 211 SMIS CSNR 692-12650; Gene profile of the non-small cell bronchopulmonary cancer with mediastinal lymph node invasion (GPN2)	Scientific coordinator	2010-2014	6.000.000
Project no. 951, SMIS-CSNR code 14056, " <b>Center Of Excellence In Translational Medicine</b> ".	Project responsible	2012-2015	43.652.966
Project code: PN-III-P3-3.1-PM-RO-CN-2018-0209, Contract number: 1 BM/2018, " <b>Prospective validation of angiogenic and inflammatory biomarkers of liver cancer recurrence after surgery</b> "	Team member	2017-2020	Total budget for Fundeni Clinical Institute: 41.280
Project code: PN-III-P4-ID-PCCF2016-0158, Contract number: PCCF 17/2018, „Mechanisms and biomarkers of response and resistance to current targeted therapies in gastric cancer" ( <a href="http://icfundeni.ro/therres/">http://icfundeni.ro/therres/</a> )	Team member	2018-2022	3.400.000
Project code: PN-III-P1-1.2-PCCDI-2017-0769, Contract number: 64PCCDI/2018, " <b>Development of radiopharmaceuticals and nuclear techniques in oncology for imagistic studies and personalized treatment at the molecular level</b> ", project acronym: ONCORAD.	Project Director	2018-2020	Total budget for Fundeni Clinical Institute: 381,836

## 11. Other mentions

Other the last decade, I have focused my studies to the oncogenic research of pancreatic cancer, colangiocarcinoma and hepatocellular carcinoma, and I have been involved in clinical correlative studies. I was part of a team of researchers from the National Cancer Center Singapore, Duke-NUS Graduate Medical School Singapore, Fundeni Clinical Institute and Koen Kaen University, who made a significant breakthrough in deciphering the molecular basis of bile duct or colangiocarcinoma (*Nat. Genetics* (2013) 45 (12): 1474-8, 1470-3). I was a team member of the project entitled "Gene Expression Profile and Biomarkers Study correlated with Clinic and pathological parameters in Pancreatic Cancer" (acronym: CEEX 56). This is one of the largest available PDAC dataset (GSE1547). The results of this study were published within the article entitled, "Combined Gene Expression Analysis of Whole-Tissue and Microdissected Pancreatic Ductal Adenocarcinoma identify Genes Specifically Overexpressed in Tumor Epithelia" in 2008 in *Hepatology* Journal. Recent findings have revealed that PDAC is a disease that can be divided into molecular subtypes. Dataset from our studies on PDAC tumor samples were included in a combined analysis of transcriptional profiles conducted by Collisson et al and published in *Nat Med* in 2011, which led to the definition of three subtypes of pancreatic cancer: classical, quasi-mesenchymal and exocrine-like. Moreover, as a team of researchers involved in the project "The role of S100A4 and MAP4K4 in the progression of pancreatic ductal adenocarcinoma" (acronym: S100MAP) I have contributed to the patent (filed with OSIM NO A / 00927) "The precise methods to establish


a personalized chemogram for pancreatic cancer treatment”. The invention will allow to establish a 3-D co-culture system using the PDAC cell co-cultured with stromal cells (PSC) in polymeric systems that mimic the extracellular matrix, which is part of PDAC microenvironment. One of the major projects of our team in which I am involved as a scientific coordinator is the CEMT, “Center of Excellence in Translational Medicine” Fundeni Clinical Institute; financing: by POS CCE. CEMT goals are to perform translational research with clinical application in patients with hepato-bilio-pancreatic diseases.

#### Collaboration in international research with:

- National Cancer Centre Singapore
- Massachusetts General Hospital Cancer Center, Harvard School of Medicine, Boston
- Johns Hopkins University School of Medicine
- Pasteur Institute - Brancusi bilateral project: Romania- France- The National Authority for Scientific Research and ACIP A24 project- Sponsor – Institut Pasteur.
- The Sheba Regenerative Medicine, Stem Cell and Tissue Engineering Center
- Department of Molecular Pathology, Tohoku University School of Medicine, Tokyo, Japan

To date, my research effort has resulted in 100+ publications (Hirsch index-16, Citation number: 1316) (<http://www.researcherid.com/rid/B-8822-2017>). Furthermore, I am the author/ co-author in 6 chapters of national books and 3 chapters of international books.

**Citation Distribution by year**



#### Relevant publications (selected):

- 1) Badea L, Herlea V, **Dima S**, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. *Hepatogastroenterology* 55: 2016-2027, 2008. *IF*: 0.904. **Times Cited: 201**
- 2) Lefter LP, **Dima S**, Sunamura M, Furukawa T, Sato Y, Abe M, Chivu M, Popescu I, Horii A. Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer. *Cancer Gene Ther* 16: 137-148, 2009. *IF*: 3.887. **Times Cited: 16.**
- 3) Chivu EM, Necula LG, Dragu D, Badea L, **Dima S**, Tudor S, Nastase A, Popescu I, Diaconu CC. Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. *Hepato-gastroenterology* 57: 1453-1464, 2010. *IF*:0.667 **Times Cited: 23.**
- 4) **Dima S**, Tanase C, Albuiescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, Duda DG, Popescu I. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. *Pancreas* 41: 1001-7, 2012. *IF*: 2.607. **Times Cited: 30**
- 5) Popescu, I.; Dima, S. O. Domino liver transplantation: How far can we push the paradigm? *Liver Transplantation* 18 (1): 22-28, 2012. **Times Cited: 33**
- 6) Yamanaka S, Olaru AV, An F, Luvsanjav D, Jin Z, Agarwal R, Tomuleasa C, Popescu I, Alexandrescu S, **Dima S**, Chivu-Economescu M, Montgomery EA, Torbenson M, Meltzer SJ, Selaru FM. MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer. *Dig Liver Dis* 44: 589-596, 2012. *Impact Factor* 2012:3.054; **Times Cited: 37.**

- 7) Chan-On W, Nairismagi ML, Ong CK, Lim WK, **Dima S**, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. *Nat Genet* 45: 1474-1478, 2013. IF: 35.209; **Times Cited: 180.**
- 8) Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, **Dima S**, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nat Genet* 45: 1470-1473, 2013. IF: 35.209; **Times Cited: 263.**
- 9) Dumitrascu T\*, **Dima S\***, Brasoveanu V, Stroescu C, Herlea V, Moldovan S, Ionescu M, Popescu I. Impact of a portal/superior mesenteric vein resection during pancreatico-duodenectomy for pancreatic head adenocarcinoma. *Minerva Chir* 2014; 69: 301-313, (\*)co-first authors. IF: 0,678. **Times Cited: 5.**
- 10) Dumitrascu T, **Dima S**, Stroescu C, Scarlat A, Ionescu M, Popescu I. Clinical value of spleen-preserving distal pancreatectomy: a case-matched analysis with a special emphasis on the postoperative systemic inflammatory response. *J Hepatobiliary Pancreat Sci* 2014; 21: 654-662, (\*) co-first authors. IF:2,994. **Times Cited: 4 .**
- 11) Ionescu-Tirgoviste C, Gagniuc PA, Gubceac E, Mardare L, Popescu I, **Dima S**, Militaru M. A 3D map of the islet routes throughout the healthy human pancreas *Sci Rep.* 2015 29;5:14634., IF: 5.578, **Times Cited: 19.**
- 12) Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma. Peng H, Ishida M, Li L, Saito A, Kamiya A, Hamilton JP, Fu R, Olaru AV, An F, Popescu I, Iacob R, **Dima S**, Alexandrescu ST, Grigorie R, Nastase A, Berindan-Neagoe I, Tomuleasa C, Graur F, Zaharia F, Torbenson MS, Mezey E, Lu M, Selaru FM. *Oncotarget.* 2015; 6(8):5666-77. IF:6.627, **Times Cited: 26.**
- 13) Chng KR, Chan SH, Ng AH, Li C, Jusakul A, Bertrand D, Wilm A, Choo SP, Tan DM, Lim KH, Soetinko R, Ong CK, Duda DG, **Dima S**, Popescu I, Wongkham C, Feng Z, Yeoh KG, Teh BT, Yongvanit P, Wongkham S, Bhudhisawasdi V, Khuntikeo N, Tan P, Pairojkul C, Ngeow J, Nagarajan N. Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in *Opisthorchis viverrini* Associated Cholangiocarcinoma. *EBioMedicine.* 2016 Jun; 8:195-202., IF:1.37, **Times Cited: 15.**
- 14) Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM, Choo SP, Myint SS, Thanan R, Nagarajan S, Lim WK, Ng CCY, Boot A, Liu M, Ong CK, Rajasegaran V, Lie S, Lim AST, Lim TH, Tan J, Loh JL, McPherson JR, Khuntikeo N, Bhudhisawasdi V, Yongvanit P, Wongkham S, Totoki Y, Nakamura H, Arai Y, Yamasaki S, Chow PKH, Chung A, Ooi LL, Lim KH, **Dima S**, et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. *Cancer Discov.* 2017. pii: CD-17-0368. IF: 20.011
- 15) Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, JengKS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, **Dima S**, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors *Sci Rep.* 2017 Mar 9; 7:44123; IF: 5.228. **Times Cited:9.**
- 16) Nastase A, Teo JY, Heng HL, Ng CC, Myint SS, Rajasegaran V, Loh JL, Lee SY, Ooi LL, Chung AY, Chow PK, Cheow PC, Wan WK, Azhar R, Khoo A, Xiu SX, Alkaff SM, Cutcutache I, Lim JQ, Ong CK, Herlea V, **Dima S**, Duda DG, Teh BT, Popescu I, Lim TK. Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors. *Am J Cancer Res.* 2017; 1;7(3):484-502. eCollection 2017. IF: 3.425.
- 17) Hong TS, Grassberger C, Yeap B, Jiang W, Wo JY, Goyal L, Clark JW, Crane CH, Koay EJ, **Dima S**, Eyle C, Popescu I, DeLaney TF, Zhu AX, Duda DG. Pretreatment plasma hepatocyte growth factor as a potential biomarker for susceptibility to radiation-induced liver dysfunction in liver cancer patients treated with radiotherapy. *Nature Precision Oncology* 2018; doi: 10.1038/s41698-018-0065-y.
- 18) Prognostic Factors in Patients with Surgical Resection of Pancreatic Neuroendocrine Tumours. **Dima SO**, Dumitrascu T, Pechianu C, Grigorie RT, Brasoveanu V, Sorop A, Lupescu I, Purnichescu-Purtan R, Croitoru A, Bacalbasa N, Tanase A, Tomescu DR, Herlea V, Popescu I. *Acta Endo (Buc)* 2018 14: 389-393

